Therapeutic filtration products company appoints John C. Houghton president and CEO, effective April 20. Houghton replaces Paul Mieyal, who stepped down as acting CEO of Nephros and will remain as a member of the board of directors. Houghton most recently served as president and CEO of CorMedix, a pharmaceutical company specializing in treatments for cardio-renal disease. Nephros submitted a revised 510(k) for its hemodiafiltration system last August, after FDA rejected its first 510(k) for the device for not showing substantial equivalence with a predicate. (See Also see "News In Brief" - Medtech Insight, 29 August, 2011..)
Start-up osteoporosis diagnostics company names Brendan K. Farrell CEO, firm says April 23. He replaces former CEO Ernie Poku, who is pursuing other opportunities within the oil industry. Crescent, which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?